https://www.thebodypro.com/category/prezista-pro

Darunavir (Prezista)

The Latest

aging face
Research

This Week in HIV Research: Playing Catchup on the Aging Front

March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.

By Barbara Jungwirth and Myles Helfand
three human skeleton models doing "see no evil, hear no evil, speak no evil"
News

This Week in HIV Research: Bone Concerns Aren’t Just for Older Folks

Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.

By Barbara Jungwirth and Myles Helfand
Boosted Darunavir Is Associated With Higher Cardiovascular Risk in D:A:D Study, but Not Atazanavir Img
Cardiovascular

Boosted Darunavir Is Associated With Higher Cardiovascular Risk in D:A:D Study, but Not Atazanavir

Cumulative use of the boosted protease inhibitor darunavir/ritonavir was associated with an approximately 60% higher rate of developing heart disease over five years, in an analysis from the D:A:D study.

By Simon Collins for HIV i-Base
No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy Registry Img

No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy Registry

The Antiretroviral Pregnancy Registry found no apparent increase in the frequency of specific birth defects with first trimester darunavir exposure.

By Polly Clayden for HIV i-Base
Updates for Prezista (Darunavir) for Use in Pregnant Women Img
News

Updates for Prezista (Darunavir) for Use in Pregnant Women

On June 17, 2016, the U.S. Food and Drug Administration approved updates to the Prezista (darunavir) labeling to include information on the use of darunavir in pregnant women.

By U.S. Food and Drug Administration
Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results Img
News

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results

Rilpivirine (Edurant) plus ritonavir-boosted darunavir (Prezista) as HIV maintenance therapy compared similarly to a three-drug regimen of a boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors, according to a study presente...

By Project Inform
Pharmacokinetics in Pregnancy: Darunavir/Ritonavir and Etravirine Img
News

Pharmacokinetics in Pregnancy: Darunavir/Ritonavir and Etravirine

Two small studies presented at the 5th International Workshop on HIV & Women evaluated the pharmacokinetics of darunavir/ritonavir (DRV/r) and etravirine (ETV) respectively in pregnancy. In both studies drug exposure was altered -- lower for DRV and ...

By Polly Clayden for HIV i-Base
Equivalent Efficacy With Lower Dose Darunavir Img

Equivalent Efficacy With Lower Dose Darunavir

A reduced dose of darunavir boosted with ritonavir was effective in two reports from Italy and Spain.

By Polly Clayden for HIV i-Base
Promo Image

Dual Therapy With Raltegravir and Darunavir

The leading U.S. HIV treatment guidelines developed by the U.S. Department of Health and Human Services (DHHS) for adults have several regimens that it recommends from which doctors and their patients can choose for the initial therapy of HIV. These ...

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
Promo Image
Conference Coverage

Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257

Primary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro...

By Simon Collins for HIV i-Base